OTC Markets OTCPK - Delayed Quote USD

Chugai Pharmaceutical Co., Ltd. (CHGCY)

Compare
21.10
-0.13
(-0.61%)
At close: January 9 at 7:00:00 PM EST
Currency in JPY All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
1,084,570,000.00
1,111,367,000.00
1,259,726,000.00
999,758,000.00
786,946,000.00
Cost of Revenue
331,206,000.00
413,306,000.00
476,251,000.00
338,147,000.00
273,465,000.00
Gross Profit
753,364,000.00
698,061,000.00
783,475,000.00
661,612,000.00
513,481,000.00
Operating Expense
266,905,000.00
258,887,000.00
250,167,000.00
239,715,000.00
212,251,000.00
Operating Income
486,459,000.00
439,174,000.00
533,308,000.00
421,897,000.00
301,230,000.00
Net Non Operating Interest Income Expense
2,396,000.00
4,647,000.00
-9,000.00
28,000.00
-1,539,000.00
Pretax Income
488,855,000.00
443,821,000.00
531,166,000.00
419,385,000.00
298,188,000.00
Tax Provision
133,814,000.00
118,349,000.00
156,737,000.00
116,390,000.00
83,455,000.00
Net Income Common Stockholders
355,041,000.00
325,472,000.00
374,429,000.00
302,995,000.00
214,733,000.00
Diluted NI Available to Com Stockholders
355,041,000.00
325,472,000.00
374,429,000.00
302,995,000.00
214,733,000.00
Basic EPS
107.89
98.92
113.82
92.14
65.33
Diluted EPS
107.88
98.90
113.78
92.08
65.27
Basic Average Shares
3,290,595.46
3,289,595.46
3,290,417.63
3,288,241.36
3,286,890.82
Diluted Average Shares
3,291,095.02
3,290,920.12
3,290,671.00
3,290,383.88
3,290,166.08
Total Operating Income as Reported
486,459,000.00
439,174,000.00
533,309,000.00
421,897,000.00
301,230,000.00
Total Expenses
598,111,000.00
672,193,000.00
726,418,000.00
577,862,000.00
485,716,000.00
Net Income from Continuing & Discontinued Operation
355,041,000.00
325,472,000.00
374,429,000.00
302,995,000.00
214,733,000.00
Normalized Income
355,041,000.00
325,472,000.00
374,429,000.00
302,995,000.00
214,733,000.00
Interest Expense
--
27,000.00
61,000.00
48,000.00
62,000.00
Net Interest Income
2,396,000.00
4,647,000.00
-9,000.00
28,000.00
-1,539,000.00
EBIT
488,377,000.00
443,848,000.00
531,227,000.00
419,433,000.00
298,250,000.00
EBITDA
488,377,000.00
443,848,000.00
531,227,000.00
419,433,000.00
298,250,000.00
Reconciled Cost of Revenue
331,206,000.00
413,306,000.00
476,251,000.00
338,147,000.00
273,465,000.00
Net Income from Continuing Operation Net Minority Interest
355,041,000.00
325,472,000.00
374,429,000.00
302,995,000.00
214,733,000.00
Normalized EBITDA
488,377,000.00
443,848,000.00
531,227,000.00
419,433,000.00
298,250,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
12/31/2020 - 8/3/2012

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

DSKYF Daiichi Sankyo Company, Limited
25.50
+1.59%
 
ALPMF Astellas Pharma Inc.
9.60
-2.04%
 
OTSKY Otsuka Holdings Co., Ltd.
25.37
-4.25%
 
BAYZF Bayer Aktiengesellschaft
20.73
+1.92%
 
DSNKY Daiichi Sankyo Company, Limited
25.97
-2.77%
 
ALPMY Astellas Pharma Inc.
9.47
-0.84%
 
GRFS Grifols, S.A.
7.29
-4.08%
 
NONOF Novo Nordisk A/S
85.80
+0.89%
 
BAYRY Bayer Aktiengesellschaft
5.12
+1.19%
 
NOVN.SW Novartis AG
91.09
-0.60%